2,5-Dimethoxy-4-ethylamphetamine

Identification

Name
2,5-Dimethoxy-4-ethylamphetamine
Accession Number
DB01467
Type
Small Molecule
Groups
Experimental, Illicit
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
9SK6K682UL
CAS number
22004-32-6
Weight
Average: 223.3113
Monoisotopic: 223.157228921
Chemical Formula
C13H21NO2
InChI Key
HXJKWPGVENNMCC-UHFFFAOYSA-N
InChI
InChI=1S/C13H21NO2/c1-5-10-7-13(16-4)11(6-9(2)14)8-12(10)15-3/h7-9H,5-6,14H2,1-4H3
IUPAC Name
1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine
SMILES
CCC1=CC(OC)=C(CC(C)N)C=C1OC

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
AcepromazineAcepromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Acrivastine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Acrivastine.Approved
Alcaftadine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Alcaftadine.Approved
Alfentanil2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlgeldrateAlgeldrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental
Alimemazine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmagateAlmagate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental
AlmasilateAlmasilate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental
AloglutamolAloglutamol may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental
Alphacetylmethadol2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
Alphaprodine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Alphaprodine.Illicit
AluminiumAluminium may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Approved
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Ammonium chlorideThe serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
Antazoline2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Astemizole2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AzaperoneAzaperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Vet Approved
Azatadine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Azatadine.Approved
Azelastine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Azelastine.Approved
Bamipine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Bamipine.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Investigational
Bezitramide2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Approved
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Brofaromine.Experimental
BromperidolBromperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Investigational
Brompheniramine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Brompheniramine.Approved
Buclizine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Buclizine.Approved
Buprenorphine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
Butorphanol2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Butyric Acid2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Butyric Acid.Experimental
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Approved
Calcium silicateCalcium silicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental
Carbinoxamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Carbinoxamine.Approved
Carfentanil2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Withdrawn
Cetirizine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Cetirizine.Approved
Chloropyramine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Chloropyramine.Approved
Chlorphenamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Chlorphenamine.Approved
Chlorphenoxamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
ChlorpromazineChlorpromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Withdrawn
Cimetidine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Cimetidine.Approved
Cinnarizine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Cinnarizine.Approved
Clemastine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Clemastine.Approved
ClomipramineClomipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
ClozapineClozapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Codeine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Cyclizine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Cyproheptadine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
DesipramineDesipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Desloratadine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
Dexbrompheniramine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dexbrompheniramine.Approved
Dexchlorpheniramine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental
Dexchlorpheniramine maleate2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
Dextromoramide2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
Dextropropoxyphene2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
Dezocine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dezocine.Approved
DibenzepinDibenzepin may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Approved
Dihydrocodeine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
Dihydroetorphine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
Dihydromorphine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
Dimenhydrinate2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dimenhydrinate.Approved
Dimetindene2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dimetindene.Approved
Dimetotiazine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dimetotiazine.Approved
Diphenhydramine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Diphenhydramine.Approved
Diphenoxylate2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
DosulepinDosulepin may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Doxepin2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Doxepin.Approved
Doxylamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPE2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of DPDPE.Investigational
DroperidolDroperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Vet Approved
Ebastine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Investigational
Emedastine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Emedastine.Approved
Epinastine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Epinastine.Approved, Investigational
Esmirtazapine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Esmirtazapine.Investigational
Ethopropazine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with 2,5-Dimethoxy-4-ethylamphetamine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Withdrawn
Ethylmorphine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
Etorphine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
Famotidine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Illicit, Withdrawn
Fentanyl2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
Fexofenadine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Fexofenadine.Approved
FluanisoneFluanisone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
Flunarizine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Vet Approved
Glutamic AcidThe serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
HarmalineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Harmaline.Experimental
Heroin2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Heroin.Approved, Illicit
HydracarbazineHydracarbazine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
Hydrocodone2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
Hydromorphone2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental
Hydroxyzine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
ImipramineImipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Ioflupane I-1232,5-Dimethoxy-4-ethylamphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
IproclozideIproclozide may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Isothipendyl2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Isothipendyl.Approved
Ketobemidone2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Ketobemidone.Approved
Ketotifen2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Ketotifen.Approved
Lafutidine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Lafutidine.Investigational
Lavoltidine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Lavoltidine.Investigational
Levocabastine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Levocabastine.Approved
Levocetirizine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl Acetate2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved
Levorphanol2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Levorphanol.Approved
LithiumLithium may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Lodoxamide2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Lodoxamide.Approved
Lofentanil2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
Loratadine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
MagaldrateMagaldrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Withdrawn
Magnesium HydroxideMagnesium Hydroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Withdrawn
Meclizine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Meptazinol2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Meptazinol.Experimental
Mepyramine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
Mequitazine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Methadone2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Methadone.Approved
Methadyl Acetate2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
Methapyrilene2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Approved
MethenamineThe serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Investigational
Metiamide2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Metiamide.Experimental
Mianserin2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Mianserin.Approved
MinaprineMinaprine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Mirtazapine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Mirtazapine.Approved
Mizolastine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
MolindoneMolindone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
MoperoneMoperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
Morphine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
Nalbuphine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Withdrawn
Nicomorphine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Nicomorphine.Experimental
Nizatidine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Nizatidine.Approved
Normethadone2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
OctamoxinOctamoxin may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Investigational
Olopatadine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
OpipramolOpipramol may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Investigational
Opium2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Opium.Approved, Illicit
OsanetantOsanetant may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Investigational
Oxatomide2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Oxatomide.Investigational
Oxycodone2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
Oxymorphone2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
Ozagrel2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
PargylinePargyline may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Pemirolast2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Pemirolast.Approved
PenfluridolPenfluridol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
Pentazocine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Investigational
PerospironePerospirone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Pethidine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Pethidine.Approved
Phenazocine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Phenindamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Withdrawn
Pheniramine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Pheniramine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with 2,5-Dimethoxy-4-ethylamphetamine.Approved
Phenoperidine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with 2,5-Dimethoxy-4-ethylamphetamine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
PipamperonePipamperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Piritramide2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Withdrawn
ProchlorperazineProchlorperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Vet Approved
Promethazine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Quifenadine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Quifenadine.Experimental
RacloprideRaclopride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Investigational
Ranitidine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Remifentanil2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
RisperidoneRisperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Investigational
Roxatidine acetate2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Withdrawn
Sufentanil2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
SultoprideSultopride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
Tapentadol2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Tapentadol.Approved
Terfenadine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Terfenadine.Withdrawn
Tesmilifene2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Investigational
ThiopropazateThiopropazate may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
ThioridazineThioridazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Thonzylamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
TiaprideTiapride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Investigational
Tilidine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Tilidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Tramadol2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Tramadol.Approved, Investigational
Tranilast2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
TrifluperidolTrifluperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
Tripelennamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
Triprolidine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Triprolidine.Approved
Tritoqualine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Tritoqualine.Experimental
VeraliprideVeralipride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental
Vitamin CThe serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
ZotepineZotepine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
PubChem Compound
27402
PubChem Substance
46504746
ChemSpider
25499
BindingDB
81965
ChEMBL
CHEMBL8224
Wikipedia
2,5-Dimethoxy-4-ethylamphetamine
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.81HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.413 mg/mLALOGPS
logP2.71ALOGPS
logP2.45ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.48 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity66.27 m3·mol-1ChemAxon
Polarizability26.07 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9187
Caco-2 permeable+0.7659
P-glycoprotein substrateNon-substrate0.6693
P-glycoprotein inhibitor INon-inhibitor0.7698
P-glycoprotein inhibitor IINon-inhibitor0.9743
Renal organic cation transporterNon-inhibitor0.8405
CYP450 2C9 substrateNon-substrate0.857
CYP450 2D6 substrateSubstrate0.7859
CYP450 3A4 substrateNon-substrate0.5212
CYP450 1A2 substrateInhibitor0.7137
CYP450 2C9 inhibitorNon-inhibitor0.9394
CYP450 2D6 inhibitorInhibitor0.7927
CYP450 2C19 inhibitorNon-inhibitor0.8757
CYP450 3A4 inhibitorNon-inhibitor0.9168
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6931
Ames testNon AMES toxic0.6594
CarcinogenicityNon-carcinogens0.7386
BiodegradationNot ready biodegradable0.8571
Rat acute toxicity3.0939 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9017
hERG inhibition (predictor II)Non-inhibitor0.6282
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Aralkylamines / Alkyl aryl ethers / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
Amphetamine or derivatives / Dimethoxybenzene / P-dimethoxybenzene / Phenylpropane / Anisole / Phenol ether / Phenoxy compound / Methoxybenzene / Aralkylamine / Alkyl aryl ether
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on July 31, 2007 07:09 / Updated on October 02, 2017 04:59